Clopidogrel Plus Aspirin in Acute Ischemic Stroke Following Thrombectomy and/or Intravenous Thrombolysis (CoPrime)
NCT06638151
Acute Ischemic Stroke, Brain Diseases
Edmonton, Alberta, Canada
View Trial DetailsNCT Number: NCT03825419
The degree of muscle loss over the course of inpatient stay will be evaluated in patients with a diagnosis of acute ischemic stroke admitted to Neurocritical Care Units and necessitating enteral nutrition.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Ankara University Faculty of Medicine, Ankara, Turkey (Türkiye)
This study is a multicenter, prospective observational study. The study period is 12 months. There are no investigational products to be followed or used in the study.
Demographic data, stroke subtype, lesion localization, anthropometric measures will be recorded. Muscle in three different anatomical sites will be measured by CT following admission in patients included in the study.
For anthropometric measurements, height, body weight, body mass index, waist circumference, triceps skin thickness and calf circumference values will be used.
The muscle mass will be measured from the paraspinal muscles at the L3 vertebra level and from the muscles around the humerus and femur on the non-paralytic side of the extremities by CT.
All patients will receive standard enteral nutritional support with a standardized calorie and protein-based protocol recommended by international guidelines. The choice of the commercial enteral product will be left to the investigator, without any encouragement or restriction for use of any commercial product.
The enteral nutrition protocol will be implemented as follows;
Patients will continue their routine follow-up in the neurology intensive care unit / stroke unit / neurology department. Daily enteral nutrition dose, complications attributed to enteral nutrition and systemic comorbidities will be recorded. Anthropometric measurements and muscle mass measurements with CT at three different locations will be repeated at the end of the second week (14 days ± 3 days) .
The study will evaluate whether or not muscle mass develops 14 days after acute ischemic stroke. The end points of the study is deterioration of anthropometric measurements and loss of muscle mass demonstrated by CT at follow up. The differences between patients with and without muscle loss will be assessed from the the aspects of demographic characteristics, ischemic stroke subtype, comorbidities and the success attained in reaching enteral nutritional goals.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients to be included in this study are required to meet all of the following inclusion criteria:
Exclusion criteria
Patients with any of the following exclusion criteria can not be included in the study:
Time frame: 14 days
Comparison of anthropometric measurements and CT based muscle mass measurements obtained at admission and at day 14 (± 3 days)
Turkish Stroke Research and Clinical Trials Network
Network
Muscle Assessment in Stroke Study (MASS): Detection of Muscle Loss in Acute Stroke Patients Who Need Enteral Nutrition
Acronym: MASS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06638151
Acute Ischemic Stroke, Brain Diseases
Edmonton, Alberta, Canada
View Trial DetailsNCT05847309
Acute Ischemic Stroke, Brain Diseases
Santiago de Compostela, A Coruña, Spain
View Trial DetailsNCT04677777
Acute Ischemic Stroke, Brain Diseases
Jacksonville, Florida, United States
View Trial DetailsNCT04451525
Acute Ischemic Stroke, Brain Diseases
Burbank, California, United States
View Trial Details